Navigation Links
New Treatment Offers Hope for Beating Aggressive Cancers
Date:4/28/2008

NASHVILLE, Tenn., April 29 /PRNewswire/ -- With an 89% initial success rate in arresting or eradicating some of the most aggressive cancers, a Nashville-based treatment is being offered to the public for the first time. According to NeoPlas Innovation Director of Research Dr. Stephen Cantrell, gathering more data to validate effectiveness is imperative, but "early human results are quite exciting. This treatment has been effective for malignant melanoma, as well as pancreatic and some of the other worst-prognosis cancers."

The new protocol incorporates a unique combination of FDA-approved drugs already known to be safe, each used by millions of people for other applications. When administered alone, these drugs show some benefit against cancer, but not enough to make a difference for most patients. The combination of the medicines, however, allows lower, more tolerable dosages and provides effectiveness not seen in previous single-drug studies.

The NeoPlas treatment shows benefit in several aggressive malignancies because it disables certain abnormal cellular processes many of them share. Based on experience and relevant lab research to date, staff members expect the best results for melanoma, pancreatic cancer, colon cancer, renal (kidney) cancer, mesothelioma, and a group of sarcomas, including osteosarcoma, chondrosarcoma and malignant fibrous histiocytoma. Patients who have other cancers can be considered on a case-by-case basis, since many of them may benefit also. Having received previous cancer treatments does not make a patient ineligible.

The regimen's most notable side-effect is fatigue. Most patients never experience nausea, vomiting, hair loss, bone marrow or immune system suppression, or other side-effects commonly affiliated with chemotherapy or radiation. An experienced physician prescribes and monitors all treatment and maintains close communication with the patient's established oncologist.

NeoPlas Innovation serves patients living throughout the country. Since treatment takes place on an outpatient basis, most patients travel to Nashville about once every two months. Additionally, physicians usually can tell if the program is working within eight weeks and quickly enable patients to make their best healthcare decisions.

NeoPlas Innovation's web site, http://www.neoplas.org , provides complete information and an interactive screening tool for patients who are considering this treatment. The center can be reached by calling 615-371-8100 or e-mailing office@neoplas.org.


'/>"/>
SOURCE NeoPlas Innovation
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. Dental Convention to Highlight Latest Breakthroughs in Oral Health Treatments
2. Study shows false memories complicate end-of-life treatment decisions
3. HHS, Cleveland Clinic Collaborate to Advance Treatment for Neurological Disorders
4. Autistic mannerisms reduced by sensory treatment
5. Mutation database helps personalized treatment of lung cancer
6. UCB Launches CIMplicity(TM) Program to Enhance Treatment Support for Cimzia(R) (certolizumab pegol) Patients and Caregivers
7. ACTwatch, to Improve Malaria Treatment, to Be Launched on World Malaria Day
8. Study finds racial disparities in smoking cessation treatment
9. Varian Medical Systems Announces Record Demand for New RapidArc(TM) Radiotherapy Treatment Capability
10. Annual Trachoma Treatments May Be Unnecessary
11. Discovery to hasten new malaria treatments, vaccines for children
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/12/2017)... ... October 12, 2017 , ... Asante, a nationally recognized ... have expanded their existing home health joint venture through an agreement, effective October ... a joint venture home health company with Asante, delivering clinically integrated care, for ...
(Date:10/12/2017)... ... 12, 2017 , ... Dr. Parsa Mohebi, the Los Angeles ... to the newly revamped Cosmetic Town journal section, featuring articles written ... known as Follicular Unit Extraction (FUE). , Dr. Mohebi says “I ...
(Date:10/12/2017)... ... 2017 , ... Leading pediatric oncology experts at Children’s National Health System ... Congress of the International Society of Paediatric Oncology (SIOP) Oct. 12-15. Chaired by ... and Blood Disorders at Children’s National, and Stephen P. Hunger, M.D., Chief of ...
(Date:10/12/2017)... ... October 12, 2017 , ... Women-owned and Grand ... Best and Brightest in Wellness® by Best and Brightest. OnSite Wellness will be ... Oct. 20 from 7:30 a.m. to 2 p.m. at the Henry Autograph Collection ...
(Date:10/12/2017)... ... October 12, 2017 , ... In the ... a year. In some states—like New York, New Jersey, Massachusetts, Texas, Virginia, Connecticut, ... retirement havens have extremely low property-tax rates, which contributes to the relatively lower ...
Breaking Medicine News(10 mins):
(Date:10/10/2017)... , Oct. 10, 2017  NDS received FDA 510(k) clearance ... a medical-grade battery-powered display stand specifically designed for endoscopy environments. An ... technology into a clinical solution to support the improvement of patient ... Innovative Design ... Wireless Solution ...
(Date:10/5/2017)... , Oct. 5, 2017  In response to ... Oral and Maxillofacial Surgeons (AAOMS) released prescribing recommendations ... to be used as a first-line therapy to ... Recognizing the value ... White Paper "Opioid Prescribing: Acute and Postoperative Pain ...
(Date:10/4/2017)... 2017 OBP Medical , a ... devices, today announced regulatory approval from ... Agência Nacional de Vigilância Sanitária (ANVISA)) to market ... retractor with integrated LED light source and smoke ... exposure of a tissue pocket or cavity during ...
Breaking Medicine Technology: